Company profile: Spruce Biosciences
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for rare endocrine diseases, including tildacerfont, a CRF1 receptor antagonist in late-stage clinical trials for classic congenital adrenal hyperplasia and potentially other conditions with elevated ACTH. Conducts CAHMELIA 203, a double-blind, placebo-controlled, dose-ranging study evaluating tildacerfont's efficacy and safety in adults with CAH.
Products and services
- CAHMELIA 203: A double-blind, placebo-controlled, dose-ranging study evaluating Tildacerfont’s efficacy and safety in adult subjects with classic congenital adrenal hyperplasia
- Endocrine Therapeutic R&D: Develops biopharmaceutical therapies for rare diseases targeting the endocrine system, advancing clinical programs like Tildacerfont
- Tildacerfont: A CRF1 receptor antagonist in late-stage clinical trials for treating classic congenital adrenal hyperplasia and potentially beneficial for other conditions with elevated ACTH levels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spruce Biosciences
Ultragenyx
HQ: United States
Website
- Description: Provider of therapeutics for rare and ultra-rare diseases, including CRYSVITA for XLH, MEPSEVII for MPS VII, and DOJOLVI for LC-FAOD. Develops investigational therapies such as UX143 (setrusumab) for osteogenesis imperfecta and GTX-102 for Angelman syndrome. Offers UltraCare patient support with assistance for insurance coverage, financial support, and access to resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultragenyx company profile →
Sairiyo Therapeutics
HQ: Canada
Website
- Description: Provider of biotechnology focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases, with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sairiyo Therapeutics company profile →
Edgewise Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of small-molecule therapies, including EDG-5506 to protect muscle fibers in rare skeletal muscle disorders (Duchenne and Becker muscular dystrophies), and EDG-7500, an oral, selective cardiac sarcomere modulator for hypertrophic cardiomyopathy and other diseases of cardiac diastolic dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Edgewise Therapeutics company profile →
XORTX Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies for progressive kidney disease: XRx-008 for ADPKD to reduce cyst growth and improve kidney function; XRx-101 to lower uric acid for acute kidney injury and issues tied to serious viral infections, including COVID-19; and XRx-225, a pre-clinical treatment for Type 2 Diabetic Nephropathy targeting chronic kidney failure and end-stage kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XORTX Therapeutics company profile →
Soleno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies, developing DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral treatment in development for Prader-Willi syndrome (PWS) and other rare endocrine disorders, designed to reduce hyperphagia, improve behavior, and manage metabolic health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Soleno Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spruce Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spruce Biosciences
2.2 - Growth funds investing in similar companies to Spruce Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spruce Biosciences
4.2 - Public trading comparable groups for Spruce Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →